iTeos Therapeutics
Monoclonal antibodies and small-molecule therapeutics targeting adenosine A2A receptor and TIGIT pathway for immuno-oncology
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2019
- Latest Form D
- $125M, Apr 2020
- Total capital
- $125M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $125M
- 1 Form D · last Apr 2020
- 79 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 7 pending · first 2015
- Rank in peer group#196 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$125M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#196 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ansbert GadickeDirectorNamed in SEC Form D filings
- CHris BuyseDirectorNamed in SEC Form D filings
- David HallalDirectorNamed in SEC Form D filings
- Detlev BiniszkiewiczDirectorNamed in SEC Form D filings
- Jonathan SkipperDirectorNamed in SEC Form D filings
- Michel DetheuxExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Priyanka BelawatDirectorNamed in SEC Form D filings
- Tim Van HauwermeirenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 15- GrantedCombinations Comprising A PYRROLIDINE-2,5-DIONE IDO1 Inhibitor And An Anti-bodyUSPTOUS 10,945,994
- GrantedNovel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseUSPTOUS 10,544,095
- GrantedTreatment Method Utilizing PYRROLIDINE-2, 5-DIONE Derivatives As IDO1 InhibitorsUSPTOUS 10,398,679
Show all 15 patent records
- Combinations Comprising A PYRROLIDINE-2,5-DIONE IDO1 Inhibitor And An Anti-bodyMar 16, 2021 · US 10,945,994Granted
- Novel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseJan 28, 2020 · US 10,544,095Granted
- Treatment Method Utilizing PYRROLIDINE-2, 5-DIONE Derivatives As IDO1 InhibitorsSep 3, 2019 · US 10,398,679Granted
- PYRROLIDINE-2, 5-DIONE Derivatives, Pharmaceutical Compositions And Methods For Use As IDO1 InhibitorsApr 24, 2018 · US 9,949,951Granted
- Novel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseJan 23, 2018 · US 9,873,690Granted
- Novel 3-(INDOL-3-YL)-PYRIDINE Derivatives, Pharmaceutical Compositions And Methods For UseSep 12, 2017 · US 9,758,505Granted
- PYRROLIDINE-2, 5-DIONE Derivatives, Pharmaceutical Compositions And Methods For Use As IDO1 InhibitorsMar 28, 2017 · US 9,603,836Granted
- Novel 4-(INDOL-3-YL)-PYRAZOLE Derivatives, Pharmaceutical Compositions And Methods For UseSep 15, 2016 · Application 15034380Pending
- Novel 4-(INDOL-3-YL)-PYRAZOLE Derivatives, Pharmaceutical Compositions And Methods For UseNov 19, 2015 · Application 14808327Pending
- Novel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseSep 24, 2015 · Application 14660082Pending
- Novel 4-(INDOL-3-YL)-PYRAZOLE Derivatives, Pharmaceutical Compositions And Methods For UseSep 8, 2015 · US 9,126,984Granted
- Novel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseApplication 62203032Pending
- PYRROLIDINE-2,5-DIONE Derivatives, Pharmaceutical Compositions And Methods For Use As IDO1 InhibitorsApplication 61996976Pending
- Novel 3-INDOL Substituted Derivatives, Pharmaceutical Compositions And Methods For UseApplication 61996975Pending
- Novel 3-(INDOL-3-YL)-PYRIDINE Derivatives, Pharmaceutical Compositions And Methods For UseApplication 61996974Pending
Related companies, and why
- Caribou BiosciencesSimilar federal contract value in Biotech · null in contracts
- Sirnaomics, Inc.Similar federal contract value in Biotech · null in contracts
- Terrestrial Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Star TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NextPoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- PRIMAL THERAPIES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .